<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03037606</url>
  </required_header>
  <id_info>
    <org_study_id>NEU-03.16</org_study_id>
    <nct_id>NCT03037606</nct_id>
  </id_info>
  <brief_title>Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets</brief_title>
  <official_title>Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets on Intragastric and Intraesophageal Acidity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neutec Ar-Ge San ve Tic A.Ş</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neutec Ar-Ge San ve Tic A.Ş</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is planned to compare the efficacy and safety of rabeprazole 50 mg DDR (dual delayed&#xD;
      release) capsules versus rabeprazole 20 mg enteric coated tablets administered once daily in&#xD;
      patients with Gastroesophageal Reflux Disease (GERD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">December 11, 2018</completion_date>
  <primary_completion_date type="Actual">December 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage time of 24-hour intragastric pH &gt;4 compared to baseline</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of 24-hour intragastric pH &gt;4 compared to baseline</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Significant increase in total measurements of median pH</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant increase in nocturnal measurements of median pH</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in reflux symptom index calculated by weekly regurgitation numbers</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in reflux symptom index calculated by weekly pyrosis numbers</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage time of 24-hour intragastric pH &gt;2 compared to baseline</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage time of 24-hour intragastric pH &gt;6 compared to baseline</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of 24-hour intragastric pH &gt;2 compared to baseline</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of 24-hour intragastric pH &gt;6 compared to baseline</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage time of 24-hour total intragastric pH &gt;4 compared to baseline</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of 24-hour total intragastric pH &gt;4 compared to baseline</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage time of 24-hour total intragastric pH &gt;4 between 11 pm and 7 am compared to baseline baseline</measure>
    <time_frame>7 days</time_frame>
    <description>rate of night reflux</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of of 24-hour total intragastric pH &gt;4 between 11 pm and 7 am compared to baseline</measure>
    <time_frame>7 days</time_frame>
    <description>rate of night reflux</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evaluation of safety of study drug (Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatments)</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QT interval obtained by ECG compared to baseline</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Rabelis DDR 50 mg Capsules and 1 placebo tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo as comparator group is not used. Since study is double-blind, one placebo capsule and tablet is added to treatment groups in order to remove the discrepancy between investigational products.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pariet 20 mg Enteric Coated Tablets and 1 placebo capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo as comparator group is not used. Since study is double-blind, one placebo capsule and tablet is added to treatment groups in order to remove the discrepancy between investigational products.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabelis DDR 50 mg Capsules</intervention_name>
    <description>Rabelis DDR 50 mg Capsules once daily for seven days.</description>
    <arm_group_label>Rabelis DDR 50 mg Capsules and 1 placebo tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pariet 20 mg Enteric Coated Tablets</intervention_name>
    <description>Pariet 20 mg Enteric Coated Tablets once daily for seven days.</description>
    <arm_group_label>Pariet 20 mg Enteric Coated Tablets and 1 placebo capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of GERD with symptoms (i.e. regurgitation, pyrosis) at least 1 or more&#xD;
             episodes a week.&#xD;
&#xD;
          -  Age ≥ 18 years and &lt;65 years&#xD;
&#xD;
          -  Helicobacter pylori (an infection) negative&#xD;
&#xD;
          -  Have a body mass index (BMI) between 18 and 33 kg/m²&#xD;
&#xD;
          -  pH&gt;4 gastric exposure &lt;25% on a 24-hour dual pH channel monitoring study performed&#xD;
             prior to screening (normal intragastric pH +2SD)&#xD;
&#xD;
          -  Pathologic intraesophageal acidity exposure (DeMeester score &gt;14.75 and/or &gt;4% of pH&lt;4&#xD;
             (at least 21 hours measured)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patiets with Barrett's stricture, gastric outlet obstruction, malignancy,&#xD;
             gastrointestinal system bleeding or any other upper gastrointestinal system pathology.&#xD;
&#xD;
          -  Patients whose Hiatus hernia is &gt; 3 cm.&#xD;
&#xD;
          -  Patients with uncontrolled or insulin dependent diabetes mellitus, symptomatic&#xD;
             gallbladder stone, active or unhealed stomach or duodenum ulcer, Zollinger-Ellison&#xD;
             syndrome, primary esophagus motility disorder, pancreatitis, inflammatory bowel&#xD;
             disease, severe lung disease, chronic liver disease, uncontrolled kidney impairment,&#xD;
             cancer (except skin cancer except melanoma), cerebrovascular disease, epilepsy.&#xD;
&#xD;
          -  Patients with history of heart failure, ventricular tachycardia, ventricular&#xD;
             fibrillation, cardiac arrest, Torsades de pointes, bradycardia, sinus node&#xD;
             dysfunction, heart attack, long QTc (&gt;450 ms for male, &gt;470 ms for female patients).&#xD;
&#xD;
          -  Patients taken PPIs or H2-blockers within 7 days and prokinetic drugs within 3 days&#xD;
             before entering the study.&#xD;
&#xD;
          -  Patients with major psychiatric disease.&#xD;
&#xD;
          -  Alcoholism and drug use.&#xD;
&#xD;
          -  Patients with pathologic laboratory tests; hemogram, sedimentation, CRP, thyroid&#xD;
             functions tests, liver enzymes.&#xD;
&#xD;
          -  Malabsorbtion.&#xD;
&#xD;
          -  Immunosuppressive patients.&#xD;
&#xD;
          -  Patients taken cortisone.&#xD;
&#xD;
          -  Patients taken other drugs that prolong QT interval.&#xD;
&#xD;
          -  Patients taken drugs that need gastric acid for optimal absorption; ketoconazole, iron&#xD;
             salts, digoxin, ampicillin esters, anticoagulants, antineoplastic agents,&#xD;
             prostaglandin analogues, sukralfat.&#xD;
&#xD;
          -  Pregnancy or breast-feeding.&#xD;
&#xD;
          -  Patients taken drugs that may affect gastrointestinal system motility or acid release.&#xD;
&#xD;
          -  History of abdominal surgery (hysterectomy, abdominal hernia repair, caesarean cases&#xD;
             may be included; cholecystectomy have to be excluded).&#xD;
&#xD;
          -  Patients taken NSAII drugs (paracetemol may be used up to 2 gr/day).&#xD;
&#xD;
          -  Patients taken antidepressants.&#xD;
&#xD;
          -  Hypersensitivty to study drugs.&#xD;
&#xD;
          -  Known allergy to peanut and soy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ege University Facult of Medicine Gastroenterology Department</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>January 27, 2017</study_first_submitted>
  <study_first_submitted_qc>January 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <last_update_submitted>December 11, 2018</last_update_submitted>
  <last_update_submitted_qc>December 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

